secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001724521-24-000101
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Biosciences adopts amended director compensation; annual meeting passes all proposals
--------------------------------------------------------------------------------

- New non-employee director compensation: $45,000 annual cash retainer; $25,000 extra for Lead Independent Director.
- Initial equity award: ~$750,000 grant-date value, 2/3 stock options and 1/3 RSUs, vesting over 3 years.
- Annual equity award: ~$400,000 grant-date value, vests fully in 12 months or until next annual meeting.
- Annual meeting results: all three Class III directors elected; Ernst & Young ratified; say-on-pay approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000101/0001724521-24-000101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000101/rcus-20240606.htm
  HTML page:      https://secwatch.observer/filing/0001724521-24-000101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer